**Template for Proposals**

 **Translational Medicine Research Grant of AZ R&D China**

**PLEASE READ THE INFORMATION BELOW BEFORE COMPLETING THE TEMPLATE**

**A. Objective of this document:**

*Objective:* The overall Objective of this document is to:

1. Capture relevant information of the proposal for its review and decision on support,
2. Serve as the basis for IP review,
3. Serve as a SOW that will be added to the contract that will be signed by the investigator and AZ.

**B. Scope of proposals**

**-Scopes of proposals:** Translational Medicine Research Grant of AZ R&D China

**C. General Instructions**

When filling out the template please comply with the following guidance:

-\*IMPORTANT\* PART 1 & 2: Required during initial proposal review. Initial proposals are required to fill out ALL sections in Part 1 (17 Sections).

- Enlarge each section as needed but please be as concise as possible.

- Include published references to support the proposal.

- DO NOT DELETE SECTIONS FROM THIS DOCUMENT or modify the formatting.

**D. Additional Information:** General\* Steps for Proposal Approval and Submission

*(\*this may vary depending on the nature of the proposal)*

1. Complete PART1 & 2 of Template. Submit to AZ for initial proposal approval.
2. After full approval of proposal then upload into the official AZ portal .

**E. Contact Information**

*R&D China*

*Chinascientificalliance@astrazeneca.com*

**PART 1: Initial Proposal**

EXECUTIVE SUMMARY

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author/PI | Institution | Translational Medicine Research Proposal Title | Molecule(s) involved | Duration |
|  |  |  |  |  |
|  |  |  |  |  |

**1.1. Full Name and Title of Investigator(s):**

**1.2. Laboratory and Institution where the work will be performed:**

* *Laboratory Name (if applicable) & Department Name*
* *Address*
* *Institution Name*
* *Email Address*

**1.3. Translational Medicine Research Proposal Title:** *Descriptive Title*

**1.4. Hypothesis:** *Statement of the hypothesis for the compound and biological target in human disease. Brief evidence why this biological pathway may be important in the disease area under investigation. (*Please be as concise as possible)

**1.5. Outline of Research Plan(all fields are required)**

* *Specific aims including scientific rationale*
* *Preliminary data (if available):* Please be as concise as possible
* *Overview of the experimental plans including rationale for choice of in vitro cell/tissue assay and/or animal model with a clear study design and details of endpoints being measured. For in vitro cell assays, provide details on any cell lines that will be used. For in vivo studies justify choice of species, animal numbers and group size (e.g. using statistics/power analysis for primary endpoints). For studies using transgenic mouse, tissue or cells include details of the genetic background with appropriate published references.*
* *Inter-dependencies, potential blockers and risk mitigation plans*  What are the key risks and inter-dependencies in the project plan i.e. is a later part of the proposal depend on successful outcome of an earlier part? What are the risk mitigation plans? Is it possible to stage the proposal with potential stop decisions?
* *Anticipated outcome of results and impact (e.g. progressing this compound as a therapy or increasing understanding of mechanisms in disease)*
* *Deliverables/Project Decision Tree/Scheme of Work Flow Plan (including timings) (Please* be as detailed as possible)

*Example of timeline table:*

|  |  |  |
| --- | --- | --- |
|  | *2023* | *2024* |
|  | *Q1* | *Q2* | *Q3* | *Q4* | *Q1* | *Q2* | *Q3* | *Q4* |
| *Experiment 1* | *X* |  |  |  |  |  |  |  |
| *Experiment 2* |  | *X* | *X* |  |  |  |  |  |
| *Deliverable 1* |  | *X* |  |  |  |  |  |  |

**1.6. Operational feasibility:** *What has/has not been done before you or members of your team?*

  *(Note: Innovative, novel approaches are welcome)*

**1.7. HGR submission plan:** *If your study requires HGR submission, please specify. (including submission plan)*

**1.8. References:** *List of key publications used in your proposal.*

**1.9. Please list any AZ compounds and quantities (dry weight, in milligrams) that are being requested:** *Typical amounts for in vitro studies are 10 – 20 mg. Amounts for in vivo studies are based on recommended dose and schedule (compound-specific); this information can be provided by AstraZeneca. Please note that for large quantities, AstraZeneca may supply compound in smaller batches over the duration of the study based on periodic review of ongoing data.*

**1.10. Please list all combinations, if any, that are being explored in the proposal. Include all non-AZ compounds as well and the source of these non-AZ compounds:**

**1.12. If a Third Party is also providing funds to do the research, please specify the source of funding:**

**PART 2: Additional Details**

**2.1. Human Tissue Use:** *Please complete if your research proposal includes the use of primary human tissue. Type “Yes” or “No” after the question below.*

*Please note: If your proposal is approved, you may be requested to provide the appropriate Ethics approval for the proposed human tissue use.*

* Can your institute assure AstraZeneca/MedImmune that any *in vitro* studies using human tissue, conducted under this proposal, will be performed in a manner consistent with the principles of AstraZeneca's Bioethics policy?

(<https://www.astrazeneca.com/sustainability/resources.html#global-policies-and-positions-0>)

**2.2. Animal Use Risk Assessment:** *Please complete if your research proposal includes the use of animals. Put a check (X) in each category that most accurately represents the animal model in the proposal.*

**Species**

**­­**[ ] Invertebrates, fish, birds, fetal/larval forms, reptiles

[ ] Mice, rats, hamsters

[ ]  Guinea pigs, rabbits, ferrets, mini pigs, genetically altered animals, other species

[ ]  Farm animals, equines, dogs, cats, harmful mutants, surgically prepared animals (any species)

[ ] Non-human primates (NHPs)

**Sensitivity**

[ ] Ex vivo studies, terminal studies, or studies on conscious animals with appropriate mitigation of pain/distress, but not involving any of the criteria in sensitivity selections below

[ ] Studies use not humanely established or unconventional methods of euthanasia

[ ] Models involve major surgery and/or repeated surgery, prolonged restraint, juvenile or neonatal animals

[ ] Models of public concern, smoking, brain surgery/instrumentation, drug dependency in NHPs, unalleviated pain, or with death required as an endpoint

**Potential for pain and distress**

[ ] Ex vivo or terminal studies

[ ] Studies involve no more than minor or transient discomfort or stress (routine dosing/sampling) or have the potential to cause prolonged pain or distress but the use of anesthetics/analgesics provides appropriate mitigation

[ ] Studies involve some pain or distress but with appropriate mitigation (most toxicity tests, surgery) or the potential to cause high degrees of pain or distress but procedures are terminated before pain or distress occurs

[ ] Studies involve potential for significant pain or distress which cannot be alleviated but are scientifically justified (acute tox studies with significant morbidity or death as an endpoint, pain models)

**Past engagement with AstraZeneca**

[ ] AZ and the external facility have had previous agreements over the last 5 years

[ ] AZ and the external facility have had no previous agreements in the last 5 years

**Name and Location\* of external facility:**

**Reputation of facility**

[ ] Facility has external regulatory oversight, AAALAC accreditation or equivalent, and no history of security/media issues in last 3 years

[ ] Facility has no external regulatory oversight, AAALAC accreditation, and no history of security/media issues in last 3 years

[ ] Facility has no external regulatory oversight, no AAALAC accreditation, and no history of security/media issues in last 3 years

[ ] Facility has no external regulatory oversight, no AAALAC accreditation and/or has a history of security/media issues in last 3 years

**For proposals involving animals, please answer the below questions:**

* Can your institute assure AstraZeneca that any *in vivo* studies using animals, conducted under this proposal, will be performed in a manner consistent with the principles of AstraZeneca's Bioethics policy?

(<https://www.astrazeneca.com/sustainability/resources.html#global-policies-and-positions-0>)

* Please list species, estimated numbers, and length of study.
* Please give details of the specific procedure the animals will undergo.
* Please indicate if this is a terminal procedure under anaesthetic, and if so, the anaesthetic used.
* Please indicate if recovery anaesthesia will be used as part of any procedures, if so, please provide details of the anaesthetic regime.
* If surgery is involved, please include details of the procedure.
* Will the animals be imaged as part of the procedure? Please indicate frequency and length of each procedure. How will the animal be monitored?
* What endpoint criteria will be used to ensure that animals under study do not suffer unduly?
* Does your institute have an ethical welfare body e.g. IACUC/ERP? If so, please give brief details on remit, membership and meeting frequency.
	1. **Contact details for compound shipments:**
* *Name*
* *Shipping Address*
* *Telephone number (Please provide a readily accessible number. Couriers may not authorize shipment of compounds in some countries without first being in direct contact with the recipient).*
* *Email Address*
	1. **Contact details for Technology Transfer Office:**
* *Name*
* *Email Address*